Regulators have a set a date of June 15, 2024, to review new indication for Augtyro, which is already available to treat lung cancer with ROS1-positive lung and has a list price of $29,000 for a 30-day supply.
The FDA has accepted for priority review Bristol Myers Squibb’s supplemental new drug application for Augtyro (repotrectinib) and assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 15, 2024. Augtyro is being reviewed as a treatment for adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. If approved, it would be indicated for patients whose cancer is locally advanced or metastatic.
NTRK gene fusions can play a role in the development of cancer. They are rare in patients with solid tumors with less than 1% of patients testing positive, though may be more frequent in patients with other cancers.
Augtyro is an oral tyrosine kinase inhibitor (TKI) that is designed to target ROS1-positive or NTRK-positive locally advanced or metastatic solid tumors, including non-small cell lung cancer. It was developed by Turning Point Therapeutic, which Bristol Myers Squibb acquired in 2022.
Related: New Lung Cancer Drug Augtyro is Now Available
In November 2023, the FDA approved Augtyro to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer NSCLC. The wholesale acquisition cost (WAC) for an adult is $29,000 based on 30-day supply of 160 mg twice a day.
The supplemental filing is based on data from the TRIDENT-1 and CARE trials. In the TRIDENT-1 phase 1/2 study, Augtyro was studied in patients with advanced solid tumors, including non-small cell lung cancer and included patients with ROS1 or NTRK fusions.
Augtyro demonstrated clinically meaningful response rates in patients with NTRK-positive locally advanced or metastatic solid tumors. Durability of response was robust, including among patients whose tumors harbor common resistance mutations, and intracranial responses were observed. Augtyro showed a safety profile that was well tolerated and generally manageable.
The CARE phase 1/2 open-label study evaluated Augtyro in pediatric and young adult patients with locally advanced or metastatic solid tumors harboring ALK, ROS1 or NTRK1-3 gene alterations.
Augtyro is also under review in the Europe Union for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer and patients with NTRK-positive solid tumors.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More